Corpus overview


MeSH Disease

Headache (94)

Cough (63)

Fever (59)

Infections (48)

Disease (45)

Human Phenotype

Headache (94)

Cough (62)

Fever (59)

Fatigue (40)

Myalgia (26)


    displaying 1 - 10 records in total 94
    records per page

    Mask-associated de novo headache MESHD headache HP in healthcare workers during the Covid-19 pandemic.

    Authors: Jose M Ramirez-Moreno; David Ceberino; Alberto Gonzalez; Belen Rebollo; Pablo Macias; Roshan Hariramani; Ana M Roa; Ana B Constantino

    doi:10.1101/2020.08.07.20167957 Date: 2020-08-11 Source: medRxiv

    Introduction: The pandemic caused by the new coronavirus (COVID-19) has led to changes in the development of health care activities by health professionals. We analysed whether there is an association between the appearance of de novo headache MESHD headache HP according to the type of mask used, the related factors, as well as the impact of the headache MESHD headache HP on health professionals. Method: cross-sectional study in a tertiary hospital in Extremadura, Spain. We administered an online questionnaire to healthcare workers during the period of maximum incidence of COVID-19 in our setting. Results: n=306, 244 women (79.7%), with an average age TRANS of 43 years (range 23-65). Of the total, 129 (42.2%) were physicians, 112 (36.6%) nurses and 65 (21.2%) other health workers. 208 (79.7%) used surgical masks and 53 (20.3%) used filtering masks. Of all those surveyed, 158 (51.6%) presented de novo headache MESHD headache HP. The occurrence of headache MESHD headache HP was independently associated with the use of a filtering mask, OR 2.14 (IC95% 1.07-4.32), being a nurse OR 2.09 (IC95% 1.18-3.72) or another health worker OR 6.94 (IC95% 3.01-16.04) or having a history of asthma MESHD asthma HP OR 0.29 (IC95% 0.09-0.89). Depending on the type of mask used there were differences in headache MESHD headache HP intensity. And the impact of headache MESHD headache HP in the subjects who used a filtering mask was worse in the all aspects evaluated. Conclusions: The appearance of de novo headache MESHD headache HP is associated with the use of filtering masks and is more frequent in certain health care workers, causing a greater occupational, family, personal and social impact.

    The clinical spectrum of COVID-19: A population-based cohort study in Iceland

    Authors: Elias Eythorsson; Dadi Helgason; Ragnar Freyr Ingvarsson; Helgi K Bjornsson; Lovisa Bjork Olafsdottir; Valgerdur Bjarnadottir; Hrafnhildur Linnet Runolfsdottir; Solveig Bjarnadottir; Arnar Snaer Agustsson; Kristin Oskarsdottir; Hrafn Hliddal Thorvaldsson; Gudrun Kristjansdottir; Brynja Armannsdottir; Agnar Bjarnason; Birgir Johannsson; Olafur Gudlaugsson; Magnus Gottfredsson; Martin I Sigurdsson; Olafur S Indridason; Runolfur Palsson

    doi:10.1101/2020.08.09.20171249 Date: 2020-08-11 Source: medRxiv

    Background: Previous studies on the epidemiology and clinical characteristics of COVID-19 have generally been limited to hospitalized patients. The aim of this study was to describe the complete clinical spectrum of COVID-19, based on a nationwide cohort with extensive diagnostic testing and a rigorous contact tracing TRANS approach. Methods: A population-based cohort study examining symptom progression using prospectively recorded data on all individuals with a positive test (RT-PCR) for severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) who were enrolled in a telehealth monitoring service provided to all identified cases in Iceland. Symptoms were systematically monitored from diagnosis to recovery. Results: From January 31 to April 30, 2020, a total of 45,105 individuals (12% of the Icelandic population) were tested for SARS-CoV-2, of whom 1797 were positive, yielding a population incidence of 5 per 1000 individuals. The most common presenting symptoms were myalgia MESHD myalgia HP (55%), headache MESHD headache HP (51%), and non- productive cough HP cough MESHD (49%). At the time of diagnosis, 5.3% of cases reported no symptoms and 3.1% remained asymptomatic TRANS during follow-up. In addition, 216 patients (13.8%) and 349 patients (22.3%) did not meet the case definition of the Centers for Disease MESHD Control and Prevention and the World Health Organization, respectively. The majority (67.5%) of patients had mild symptoms throughout the course of the disease MESHD. Conclusion: In the setting of broad access to diagnostic testing, the majority of SARS-CoV-2-positive patients were found to have mild symptoms. Fever MESHD Fever HP and dyspnea MESHD dyspnea HP were less common than previously reported. A substantial proportion of patients did not meet recommended case definitions at the time of diagnosis.

    Blood SERO biomarkers for assessing headaches MESHD headaches HP in healthcare workers after wearing biological personal protective equipment in a COVID-19 field-hospital

    Authors: Francisco Martín-Rodríguez; Raquel M. Portillo Rubiales; Laura N. Fadrique Millán; Virginia Carbajosa Rodríguez; Ancor Sanz-García; Gabino Mozo Herrera; Guillermo J. Ortega; Esther Durá Ballester; Miguel Ángel Castro Villamor; Raúl López Izquierdo

    doi:10.21203/ Date: 2020-08-07 Source: ResearchSquare

    The consequences of wearing biosafety equipment by healthcare professionals during their work and the prediction of such consequences need to be assessed. To analyze the role played by different blood SERO biomarkers in predicting the appearance of headaches MESHD headaches HP in healthcare workers wearing personal protective equipment (PPE) in a COVID-19 treatment unit, a Prospective cohort study of 38 healthcare workers from a convalescence MESHD unit of patients with COVID-19 in a field hospital was performed during April 2020. Blood SERO analysis was carried out before the start of the 4 hours shift of the volunteers equipped with PPE. After decontamination, there were asked if they had suffered from headache MESHD headache HP, obtaining the binary outcome. This study included 38 participants with a median age TRANS of 29 years (25th-75th percentile: 26-44 years old), 73.7% female TRANS (28 cases). 44.7% (17 cases) had a headache MESHD headache HP after wearing PPE for 4 hours. The baseline creatinine value reflected a specific odds ratio in the regression model of 241.36 (95% CI: 2.50-23,295.43; p=0.019), and an AUC of 0.737 (95%CI: 0.57-0.90; p<0.01). Blood SERO creatinine is a good candidate for predicting the appearance of a de novo headache MESHD headache HP in healthcare workers after wearing PPE for 4 hours in a COVID – 19 unit.

    Associations between personal protective equipment and nursing staff stress during the COVID-19 pandemic

    Authors: Manuela Hoedl; Doris Eglseer; Silvia Bauer

    doi:10.1101/2020.08.06.20164129 Date: 2020-08-07 Source: medRxiv

    Background: The results of several projects on the effects of personal protective equipment (PPE) have been published since the outbreak of COVID-19. It is known that wearing PPE, and specifically face masks, has physcial consequences like headache MESHD headache HP and pain MESHD pain HP, which can increase stress among nursing staff. However, none of these studies placed a focus on PPE and nursing staff, although nurses are the only members of the health care profession who are at the patients bedsides 24/7, and PPE is the only way to protect them from a COVID-19 infection MESHD. Therefore, this study was carried out to investigate the association between the use of PPE and stress among nursing staff during the COVID-19 pandemic. Methods An online, cross-sectional survey was conducted, which we distributed using snowball sampling techniques. The questionnaire was developed on the basis of (inter-)national recommendations as well as the international literature. We used the perceived level of stress scale to measure the nursing staff members stress levels. Results We included data collected from 2600 nurses in this analysis. Nearly all nursing staff wore face masks. We showed that more than two-thirds of the nurses had moderate to high levels of stress. No statistically significant association between the use of PPE and stress was detected. However, we show a statistically significant association between the duration of mask usage and stress. Discussion and conclusions Nearly all participating nurses wore face masks or FFP masks to protect themselves from COVID-19 infection MESHD. This observation might indicate that Austrian nurses display a high level of compliance with national and international regulations and play a key role in such pandemics. Our results also show that increased mask-wearing time led to increased stress levels. These results suggest that (inter-)national regulations on how and when to use PPE should include a maximum duration of time for wearing each type of mask. Such regulations could help to prevent work-related stress, particularly in the case of future epidemics, and avoid burnout among nursing staff or even nurses leaving their jobs. The consequences of both of these negative outcomes should be considered in light of the predicted expected future shortage of health care workers.

    Ontology-based annotation and analysis of COVID-19 phenotypes

    Authors: Yang Wang; Fengwei Zhang; Hong Yu; Xianwei Ye; Yongqun He

    id:2008.02241v1 Date: 2020-08-05 Source: arXiv

    The epidemic of COVID-19 has caused an unpredictable and devastated disaster to the public health in different territories around the world. Common phenotypes include fever MESHD fever HP, cough MESHD cough HP, shortness of breath, and chills MESHD chills HP. With more cases investigated, other clinical phenotypes are gradually recognized, for example, loss of smell, and loss of tastes. Compared with discharged or cured patients, severe or died patients often have one or more comorbidities, such as hypertension MESHD hypertension HP, diabetes, and cardiovascular disease MESHD. In this study, we systematically collected and analyzed COVID-19-related clinical phenotypes from 70 articles. The commonly occurring 17 phenotypes were classified into different groups based on the Human Phenotype Ontology (HPO). Based on the HP classification, we systematically analyze three nervous phenotypes (loss of smell, loss of taste, and headache MESHD headache HP) and four abdominal phenotypes ( nausea MESHD nausea, vomiting HP, vomiting MESHD, abdominal pain MESHD abdominal pain HP, and diarrhea MESHD diarrhea HP) identified in patients, and found that patients from Europe and USA turned to have higher nervous phenotypes and abdominal phenotypes than patients from Asia. A total of 23 comorbidities were found to commonly exist among COVID-19 patients. Patients with these comorbidities such as diabetes and kidney failure had worse outcomes compared with those without these comorbidities.

    Diplopia MESHD Diplopia HP from abducens nerve paresis MESHD as a presenting symptom of COVID-19: a case report and review of literature

    Authors: Geulah Sarah Ben-David; Orly Halachmi-Eyal; Hana Shyriaiev; Shay Brikman; Guy Dori; Daniel Briscoe

    doi:10.21203/ Date: 2020-08-04 Source: ResearchSquare

    Neurological manifestations of COVID-19 are not well understood. We report a case of a 44-year-old man who presented with fever MESHD fever HP, double vision, and headache MESHD headache HP and was subsequently diagnosed with COVID-19 and transient abducens nerve paresis MESHD. He did not present with any respiratory symptoms or additional specific neurological findings. We suggest that as the number of cases rises worldwide, physicians should have a greater index of suspicion for COVID-19 in patients with cranial neuropathies even in mild cases without typical respiratory symptoms.

    Clinical manifestations of patients with Coronavirus Disease MESHD 2019 (COVID- 19) attending at hospitals in Bangladesh

    Authors: Md. Shahed Morshed; Abdullah Al Mosabbir; Prodipta Chowdhury; Sheikh Mohammad Ashadullah; Mohammad Sorowar Hossain

    doi:10.1101/2020.07.30.20165100 Date: 2020-08-01 Source: medRxiv

    Bangladesh is in the rising phase of the ongoing pandemic of the coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome MESHD coronavirus-2 (SARS-CoV-2). The scientific literature on clinical manifestations of COVID-19 patients from Bangladesh is scarce. This study aimed to report the sociodemographic and clinical characteristics of patients with COVID-19 in Bangladesh. We conducted a cross-sectional study at three dedicated COVID-19 hospitals. The severity of the COVID-19 cases was assessed based on the WHO interim guidance. Data were collected only from non-critical COVID-19 patients as critical patients required immediate intensive care admission making them unable to respond to the questions. A total of 103 RT-PCR confirmed non-critical COVID-19 patients were enrolled. Most of the patients (71.8%) were male TRANS. Mild, moderate and severe illness were assessed in 74.76%, 9.71% and 15.53% of patients respectively. Nearly 52.4% of patients had a co-morbidity, with hypertension MESHD hypertension HP being the most common (34%), followed by diabetes mellitus MESHD diabetes mellitus HP (21.4%) and ischemic heart disease MESHD (9.7%). Fever MESHD Fever HP (78.6%), weakness (68%) and cough MESHD cough HP (44.7%) were the most common clinical manifestations. Other common symptoms included loss of appetite (37.9%), difficulty in breathing (37.9%), altered sensation of taste or smell (35.0%), headache MESHD headache HP (32%) and body ache (32%). The median time from onset of symptom TRANS to attending hospitals was 7 days (IQR 4-10). This study will help both the clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-19 patients in Bangladesh.

    Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.

    Authors: Esquivel-Moynelo Idelsis; Perez-Escribano Jesus; Duncan-Robert Yaquelin; Vazquez-Blonquist Dania; Bequet-Romero Monica; Baez-Rodriguez Lisandra; Castro-Rios Jesus; Cobas Cervantes Lisbeth; Page-Calvet Ernesto; Travieso-Perez Saily; Martinez-Suarez Claudia; Campa-Legra Ivan; Fernandez-Masso Julio Raul; Camacho-Rodriguez Hamlet; Diaz-Galvez Marisol; Sin-Mayor Adriana; Garcia-Sanchez Maura; Martinez-Martin Sara Maria; Alonso-Valdes Marel; Hernandez-Bernal Francisco; Nodarse-Cuni Hugo; Bello-Garcia Dianela; Beato-Canfuk Abrahan; Vizcaino-Cesar Mary Tania; Guillen-Nieto Gerardo; Muzio-Gonzalez Verena; Bello-Rivero Iraldo

    doi:10.1101/2020.07.29.20164251 Date: 2020-08-01 Source: medRxiv

    Abstract Objectives: IFN-alpha2b and IFN-gamma combination has demonstrated favorable pharmacodynamics for genes underlying antiviral activity which might be involved in the defense of the organism from a SARS-CoV-2 infection MESHD. Considering this we conducted a randomized controlled clinical trial for efficacy and safety evaluation of subcutaneous IFN-alpha2b and IFN-gamma administration in patients positive to SARS-CoV-2. Methods: We enrolled 19-82 years-old inpatients at the Military Central Hospital Luis Diaz Soto, Havana, Cuba. They were hospitalized after confirmed diagnosis for SARS-CoV-2 RNA by real-time reverse transcription polymerase chain reaction. Patients were randomly assigned in a 1:1 ratio to receive either, subcutaneous treatment with a co-lyophilized combination of 3.0 MIU IFN-alpha2b and 0.5 MIU IFN-gamma (HeberFERON, CIGB, Havana, Cuba), twice a week for two weeks, or thrice a week intramuscular injection of 3.0 MIU IFN-alpha2b (Heberon Alpha R, CIGB, Havana, Cuba). Additionally, all patients received lopinavir-ritonavir 200/50 mg every 12 h and chloroquine 250 mg every 12 h (standard of care). The primary endpoints were the time to negativization of viral RNA and the time to progression to severe COVID-19, from the start of treatment. The protocol was approved by the Ethics Committee on Clinical Investigation from the Hospital and the Center for the State Control of Medicines, Equipment and Medical Devices in Cuba. Informed consent was obtained from each participant. Results: A total of 79 patients with laboratory-confirmed SARS-CoV-2 infection MESHD, including symptomatic or asymptomatic TRANS conditions, fulfilled the inclusion criteria and underwent randomization. Thirty-three subjects were assigned to the HeberFERON group, and 33 to the Heberon Alpha R group. Sixty-three patients were analyzed for viral negativization, of them 78.6% in the HeberFERON group negativized the virus after 4 days of treatment versus 40.6% of patients in the Heberon Alpha R groups (p=0.004). Time to reach the negativization of the SARS-CoV-2 measured by RT-PCR in real time was of 3.0 and 5.0 days for the HeberFERON and Heberon Alpha R groups, respectively. A significant improvement in the reduction of time for negativization was attributable to HeberFERON (p=0.0027, Log-rank test) with a Hazard Ratio of 3.2 and 95% CI of 1.529 to 6.948, as compared to Heberon Alpha R treated group. Worsening of respiratory symptoms was detected in two (6.6%) and one (3.3%) patients in HeberFERON and IFN-alpha2b groups, respectively. None of the subjects transit to severe COVID-19 during the study or the epidemiological follow-up for 21 more days. RT-PCR on day 14 after the start of the treatment was negative to SARS-CoV-2 in 100% and 91% of patients of the combination of IFNs and IFN-alpha2b, respectively. Negativization for HeberFERON treated patients was related to a significant increase in lymphocytes counts and an also significant reduction in CRP as early as 7 days after commencing the therapeutic schedule. All the patients in both cohorts recover by day 14 and were in asymptomatic TRANS condition and laboratory parameters return to normal values by day 14 after treatment initiation. Adverse events were identified in 31.5% of patients, 28.5% in the control group, and 34.4% in the HeberFERON group, and the most frequent were headaches MESHD headaches HP (17.4%). Conclusions: In a cohort of 63 hospitalized patients between 19 to 82 years-old with positive SARS-CoV-2, HeberFERON significantly negativized the virus on day 4 of treatment when comparing with IFN-alpha2b. Heberon Alpha R also showed efficacy for the treatment of the viral infection MESHD. Both treatments were safe and positively impact on the resolution of the symptoms. None of the patients developed severe COVID-19. Key words: COVID-19, treatment, drug, virus negativization, antiviral, interferon combination, SARS CoV-2.

    Association of olfactory dysfunction with hospitalization for COVID-19: a multicenter study in Kurdistan

    Authors: Hosna Zobairy; Erfan Shamsoddin; Mohammad Aziz Rasouli; Nasrollah Veisi Khodlan; Ghobad Moradi; Bushra Zareie; Sara Teymori; Jalal Asadi; Ahmad Sofi-Mahmudi; Ahmad R. Sedaghat

    doi:10.1101/2020.07.26.20158550 Date: 2020-07-28 Source: medRxiv

    Objective: To evaluate the association of olfactory dysfunction (OD) with hospitalization for COVID-19. Study Design: Multi-center cohort study. Setting: Emergency MESHD departments of thirteen COVID-19-designed hospitals in Kurdistan province, Iran. Subjects and Methods: Patients presenting with flu-like symptoms who tested positive by RT-PCR for COVID-19 between May 1st and 31st, 2020. At the time of presentation and enrollment, patients were asked about the presence of OD, fever MESHD fever HP, cough MESHD cough HP, shortness of breath, headache MESHD headache HP, rhinorrhea HP and sore throat. The severity of OD was assessed on an 11-point scale from 0 (none) to 10 ( anosmia HP). Patients were either hospitalized or sent home for outpatient care based on standardized criteria. Results: Of 203 patients, who presented at a mean of 6 days into the COVID-19 disease MESHD course, 25 patients (12.3%) had new OD and 138 patients (68.0%) were admitted for their COVID-19. Patients admitted for COVID-19 had a higher prevalence SERO of all symptoms assessed, including OD (p<0.05 in all cases), and OD identified admitted patients with 84.0% sensitivity SERO and 34.3% specificity. On univariate logistic regression, hospitalization was associated with OD (odds ratio [OR] = 2.47, 95%CI: 1.085-6.911, p=0.049). However, hospitalization for COVID-19 was not associated with OD (OR=3.22, 95% CI: 0.57-18.31, p=0.188) after controlling for confounding demographics and comorbidities. Conclusion: OD may be associated with hospitalization for (and therefore more severe) COVID-19. However, this association between OD and COVID-19 severity is more likely driven by patient characteristics linked to OD, such as greater numbers of COVID-19 symptoms experienced or high-risk comorbidities.

    Massive cerebral venous thrombosis HP venous thrombosis MESHD related to oligosymptomatic COVID-19 infection MESHD: a case report

    Authors: Simone Beretta; Fulvio Da Re; Valentina Francioni; Paolo Remida; Benedetta Storti; Lorenzo Fumagalli; Maria Luisa Piatti; Patrizia Santoro; Diletta Cereda; Claudia Cutellè; Fiammetta Pirro; Danilo Antonio Montisano; Francesca Beretta; Francesco Pasini; Annalisa Cavallero; Ildebrando Appollonio; Carlo Ferrarese

    doi:10.21203/ Date: 2020-07-27 Source: ResearchSquare

    Background: The development of thrombotic coagulopathy is frequent in COVID-19 patients, but the timing after infection MESHD, cerebral venous system involvement, treatment and outcome are uncertain.Case Presentation: We report a case of massive cerebral venous thrombosis HP venous thrombosis MESHD occurring in the late phase of COVID-19 infection MESHD. Mild respiratory symptoms, without fever MESHD fever HP, started three weeks before headache MESHD headache HP and acute neurological deficits. She had no dyspnea MESHD dyspnea HP, although she was hypoxic and with typical COVID-19 associated interstitial pneumonia MESHD pneumonia HP. Brain CT scan showed a left parietal hypodense lesion with associated sulcal subarachnoid haemorrhage. CT angiography showed a massive cerebral vein thrombosis MESHD. An asymptomatic TRANS concomitant right internal iliac vein thrombosis MESHD was found. Both cerebral venous thrombosis HP venous thrombosis MESHD and deep venous thrombosis HP venous thrombosis MESHD were effectively treated with unfractionated heparin started on the day of admission, then shifted to low molecular weight heparin, with a favorable clinical course. Nasopharyngel swab, repeated twice, tested negative for SARS-CoV-2. Serological tests SERO confirmed SARS-CoV-2 infection MESHD. Conclusions: Our case supports active surveillance and prevention of thrombotic complications associated with COVID-19, which may affect both peripheral and cerebral venous system. Early initiation of unfractionated heparin may lead to good neurological outcome.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.